Immunic Inc - IMUX STOCK NEWS

On March 2, 2023, Immunic (Nasdaq: IMUX) announced its participation in several key investor and scientific conferences throughout March. Notable events include the BioCapital Europe conference on March 9 in Amsterdam where CEO Daniel Vitt will present at 3:20 PM CET. Additionally, the company will attend the 2023 American Academy of Dermatology Annual Meeting from March 17-21 in New Orleans, and the 32nd Annual Meeting of the Society for Virology from March 28-31 in Germany, featuring multiple poster presentations by its preclinical team.

Immunic, Inc. (NASDAQ: IMUX) reported a net loss of approximately $120.4 million for the year ending December 31, 2022, compared to a loss of $92.9 million in 2021. Their cash position stood at $116.4 million, expected to sustain operations into Q4 2024. Key developments include upcoming interim results from the Phase 2 CALLIPER trial for vidofludimus calcium in progressive MS and results from the ongoing Phase 1 trial of IMU-856 for celiac disease, both anticipated mid-2023. R&D expenses rose to $71.3 million, with significant costs related to ongoing clinical programs. An impairment of goodwill totaling $33 million was also recorded due to a stock price decline following trial announcements.

Immunic, Inc. (Nasdaq: IMUX) announced promising results from the open-label extension of its phase 2 EMPhASIS trial for vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Key findings show a low rate of confirmed disability worsening (CDW): only 1.6% in treatment arms versus 3.7% in placebo. After 48 weeks, 97.2% of patients were free from 12-week CDW. The data will be presented at ACTRIMS Forum 2023 in San Diego, highlighting vidofludimus calcium's potential against historical MS treatments. CEO Daniel Vitt expressed optimism about the ongoing phase 3 ENSURE program and phase 2 CALLIPER trial, set for data updates later this year.

Immunic, Inc. (Nasdaq: IMUX) has scheduled a release of its financial results for the fourth quarter and year ended December 31, 2022, on February 23, 2023, before U.S. market opening. A webcast will follow at 8:00 am ET, providing corporate updates. The company is advancing its pipeline of selective oral immunology therapies aimed at chronic inflammatory and autoimmune diseases. Key products include vidofludimus calcium (IMU-838) for multiple sclerosis, IMU-935 for psoriasis and prostate cancer, and IMU-856 focusing on bowel barrier restoration. For more details, visit Immunic's official website.

Immunic, Inc. (NASDAQ: IMUX) has announced a virtual Celiac Disease R&D Day set for February 9, 2023, from 11:00 am to 1:00 pm ET. During this webcast, management, including CEO Daniel Vitt, will discuss the complexities of celiac disease and its treatment, emphasizing the unmet medical needs of patients. Key opinion leaders Joseph A. Murray and Michael Schumann will present their insights on the immune response and intestinal barrier function in celiac disease. The event highlights Immunic's commitment to developing therapeutic options beyond the current gluten-free diet. Archived footage will be available after the event.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, announced its participation in several key scientific and investor conferences throughout February 2023. On February 2, Darius-Jean Namdjou will join a panel on EU and UK pharmacovigilance regulations in London. A webcast on celiac disease research featuring experts will be held on February 9. CEO Daniel Vitt will present a company overview at the SVB Securities Global Biopharma Conference on February 16. Additionally, Robert J. Fox will present data on the phase 2 EMPhASIS trial at the ACTRIMS Forum in San Diego from February 23-25. More details and registration links are available on Immunic's website.

Immunic, Inc. (Nasdaq: IMUX) announced promising results from its phase 2 EMPhASIS trial of vidofludimus calcium (IMU-838) for treating relapsing-remitting multiple sclerosis (RRMS). The drug demonstrated a low rate of confirmed disability worsening (1.6%) compared to 3.7% in the placebo group over a 24-week period. Long-term treatment showed 97.6% of patients free from disability worsening after 48 weeks. The company anticipates further data from its phase 3 ENSURE program and phase 2 CALLIPER trial in 2023, highlighting the drug's potential through its neuroprotective and anti-inflammatory effects.

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company, will participate in several investor and scientific conferences during November and December 2022. Key events include:

• November 17: A webcast discussing multiple sclerosis research and vidofludimus calcium development at 11:00 am ET.
• December 1: Fireside chat at the Piper Sandler Healthcare Conference at 12:30 pm ET.
• November 29 - December 2: Presentations at various conferences, including a poster on IMU-856 in Perth, Australia.

For more details, visit www.imux.com.

Immunic, Inc. (Nasdaq: IMUX) reported a net loss of approximately $21.2 million for Q3 2022, a loss of $0.69 per share, compared to $19.3 million the previous year. Cash and equivalents totaled $72.8 million as of September 30, 2022, bolstered by a $60 million private placement in October. The interim analysis of the phase 1b trial for IMU-935 in psoriasis showed no significant benefit over placebo. Despite this, Immunic remains optimistic about the drug's potential. They also reported positive results for IMU-856 and are advancing their phase 2 CALLIPER trial for IMU-838 in multiple sclerosis.